Acrivon Therapeutics, Inc. updated its corporate presentation for the Oppenheimer 33rd Annual Healthcare Conference, disclosing $169.6 million of cash and marketable securities as of December 31, 2022 and confirming its projected cash runway into at least the fourth quarter of 2024.